Potential Therapeutic Strategies to Overcome Acquired Resistance to BRAF or MEK Inhibitors in BRAF Mutant Cancers

@inproceedings{Corcoran2011PotentialTS,
  title={Potential Therapeutic Strategies to Overcome Acquired Resistance to BRAF or MEK Inhibitors in BRAF Mutant Cancers},
  author={Ryan Bruce Corcoran and Jeffrey Settleman and Jeffrey A. Engelman},
  booktitle={Oncotarget},
  year={2011}
}
Recent clinical trials with selective inhibitors of the BRAF and MEK kinases have shown promising results in patients with tumors harboring BRAF V600 mutations. However, as has been observed previously with similarly successful targeted therapies, acquired resistance to these agents is an emerging problem that limits their clinical benefit. Several recent studies from our laboratory and others have investigated the causes of acquired resistance to BRAF and MEK inhibitors, and multiple… CONTINUE READING

From This Paper

Figures, tables, and topics from this paper.
60 Citations
54 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 60 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 54 references

Similar Papers

Loading similar papers…